Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2019

01-10-2019 | Meeting Report

“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24–26th 2018, Halle/Saale, Germany

Authors: André Steven, Barbara Seliger

Published in: Cancer Immunology, Immunotherapy | Issue 10/2019

Login to get access

Excerpt

This article summarizes the highlights of the presentations during the XIVth “Tumor Immunology Meets Oncology” (TIMO) symposium, which was held May 24–26th 2018 at the Martin-Luther-University Halle-Wittenberg in Halle/Saale, Germany. Basic scientists, translational researchers and clinicians provided talks on topics ranged from immune escape mechanisms, immune modulation, composition of the tumor microenvironment and immune metabolism to the design and optimization of immunotherapies. …
Metadata
Title
“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24–26th 2018, Halle/Saale, Germany
Authors
André Steven
Barbara Seliger
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 10/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02329-5

Other articles of this Issue 10/2019

Cancer Immunology, Immunotherapy 10/2019 Go to the issue

Focussed Research Review

Unlocking the therapeutic potential of primary tumor-draining lymph nodes

Focussed Research Review

T cell engineering for adoptive T cell therapy: safety and receptor avidity

Original Article

Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells

Original Article

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

Original Article

ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy

Focussed Research Review

The role of immune infiltrates as prognostic biomarkers in patients with breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits